Log in
OTCMKTS:IGXT

IntelGenx Technologies Stock Forecast, Price & News

$0.22
-0.02 (-8.33 %)
(As of 12/1/2020 12:00 AM ET)
Add
Compare
Today's Range
$0.19
Now: $0.22▼
$0.27
50-Day Range
$0.14
MA: $0.18▼
$0.27
52-Week Range
$0.12
Now: $0.22▼
$0.60
Volume630,848 shs
Average Volume404,395 shs
Market Capitalization$24.26 million
P/E RatioN/A
Dividend YieldN/A
Beta2.07
IntelGenx Technologies Corp., a drug delivery company, focuses on the development of novel oral thin film products for the pharmaceutical market. It offers RIZAPORT, an oral thin film formulation of rizatriptan benzoate for the treatment of acute migraines. The company's products under development comprise INT0004/2006, an antidepressant; INT0046/2018 for adult use; INT0007/2006 for the treatment of erectile dysfunction; INT0008/2008 for migraine; INT0010/2006 for the treatment of neuropathic pain and nausea in cancer patients; INT0027/2011 to treat opioid dependence; INT0036/2013 for schizophrenia; and INT0043/2015 to treat Alzheimer's disease. It is also developing INT0037/2013, INT0039/2013, and INT0040/2014. The company has co-development and commercialization agreements with RedHill Biopharma Ltd., Par Pharmaceutical Companies, Inc., and Endo Ventures Ltd.; licensing, development, and supply agreement with Tilray, Inc., Gensco Pharma, and Insud Pharma; and development agreement with Cynapsus Therapeutics Inc. IntelGenx Technologies Corp. was founded in 2003 and is headquartered in Montreal, Canada.
IntelGenx Technologies logo

Beat the Market (BTM) Rank™

Analyst Opinion: 3.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank™

1.20 out of 5 stars


Industry, Sector and Symbol

Stock Exchange OTCMKTS
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:IGXT
Previous Symbol
CUSIP45822R101
CIK1098880
Webwww.intelgenx.com
Phone514-331-7440
Employees48

Debt

Debt-to-Equity Ratio3.86
Current Ratio0.75
Quick Ratio0.69

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$740,000.00
Price / Sales32.78
Cash FlowN/A
Price / Cash FlowN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net Income$-10,660,000.00
Net Margins-1,025.30%
Return on Equity-774.28%
Return on Assets-73.47%

Miscellaneous

Outstanding Shares110,260,000
Market Cap$24.26 million
Next Earnings Date3/25/2021 (Estimated)
OptionableNot Optionable
$0.22
-0.02 (-8.33 %)
(As of 12/1/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive IGXT News and Ratings via Email

Sign-up to receive the latest news and ratings for IGXT and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











IntelGenx Technologies (OTCMKTS:IGXT) Frequently Asked Questions

How has IntelGenx Technologies' stock price been impacted by Coronavirus (COVID-19)?

IntelGenx Technologies' stock was trading at $0.3950 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, IGXT shares have decreased by 44.3% and is now trading at $0.22.
View which stocks have been most impacted by COVID-19.

Do Wall Street analysts recommend investors buy shares of IntelGenx Technologies?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IntelGenx Technologies in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for IntelGenx Technologies or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than IntelGenx Technologies?

Wall Street analysts have given IntelGenx Technologies a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but IntelGenx Technologies wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is IntelGenx Technologies' next earnings date?

IntelGenx Technologies is scheduled to release its next quarterly earnings announcement on Thursday, March 25th 2021.
View our earnings forecast for IntelGenx Technologies.

How were IntelGenx Technologies' earnings last quarter?

IntelGenx Technologies Corp. (OTCMKTS:IGXT) announced its quarterly earnings data on Thursday, November, 12th. The company reported ($0.01) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.02) by $0.01. IntelGenx Technologies had a negative return on equity of 774.28% and a negative net margin of 1,025.30%.
View IntelGenx Technologies' earnings history.

What price target have analysts set for IGXT?

2 Wall Street analysts have issued twelve-month price targets for IntelGenx Technologies' stock. Their forecasts range from $0.50 to $1.20. On average, they anticipate IntelGenx Technologies' share price to reach $0.85 in the next year. This suggests a possible upside of 286.4% from the stock's current price.
View analysts' price targets for IntelGenx Technologies.

Are investors shorting IntelGenx Technologies?

IntelGenx Technologies saw a drop in short interest during the month of November. As of November 15th, there was short interest totaling 18,000 shares, a drop of 38.8% from the October 31st total of 29,400 shares. Based on an average daily trading volume, of 235,400 shares, the short-interest ratio is currently 0.1 days.
View IntelGenx Technologies' Short Interest.

Who are some of IntelGenx Technologies' key competitors?

Some companies that are related to IntelGenx Technologies include Tonix Pharmaceuticals (TNXP), Lantern Pharma (LTRN), Kazia Therapeutics (KZIA), Liminal BioSciences (LMNL), Clearside Biomedical (CLSD), Aravive (ARAV), Eyenovia (EYEN), NeuroBo Pharmaceuticals (NRBO), Aptorum Group (APM), Oramed Pharmaceuticals (ORMP), American BriVision (Holding) (ABVC), Capricor Therapeutics (CAPR), NervGen Pharma (NGENF), Marker Therapeutics (MRKR) and Galmed Pharmaceuticals (GLMD).
View all competitors.

What other stocks do shareholders of IntelGenx Technologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other IntelGenx Technologies investors own include Cronos Group (CRON), KemPharm (KMPH), Exelixis (EXEL), SemiLEDs (LEDS), New Residential Investment (NRZ), Anavex Life Sciences (AVXL), Ampio Pharmaceuticals (AMPE), BioDelivery Sciences International (BDSI), BIOLASE (BIOL) and Ocugen (OCGN).

Who are IntelGenx Technologies' key executives?

IntelGenx Technologies' management team includes the following people:
  • Dr. Horst G. Zerbe, Chairman, CEO & Chairman of Scientific Advisory Board (Age 73, Pay $233.65k)
  • Mr. André Godin C.A., CPA, CPA, CA, Pres & CFO (Age 56, Pay $216.31k)
  • Dr. Dana Matzen, VP of Bus. & Corp. Devel. (Age 42, Pay $166.19k)
  • Ms. Nadine Paiement, Vice-Chair of Scientific Advisory Board and VP of R&D - IntelGenx Corp (Age 43, Pay $135.67k)
  • Ms. Ingrid Zerbe, Corp. Sec. (Age 66)
  • Stephen Kilmer, Investor Relations Officer
  • Mr. Rodolphe Obeid Ph.D., VP of Operations - IntelGenx Corp (Age 40)

What is IntelGenx Technologies' stock symbol?

IntelGenx Technologies trades on the OTCMKTS under the ticker symbol "IGXT."

How do I buy shares of IntelGenx Technologies?

Shares of IGXT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is IntelGenx Technologies' stock price today?

One share of IGXT stock can currently be purchased for approximately $0.22.

How big of a company is IntelGenx Technologies?

IntelGenx Technologies has a market capitalization of $24.26 million and generates $740,000.00 in revenue each year. IntelGenx Technologies employs 48 workers across the globe.

What is IntelGenx Technologies' official website?

The official website for IntelGenx Technologies is www.intelgenx.com.

How can I contact IntelGenx Technologies?

IntelGenx Technologies' mailing address is 6420 ABRAMS, VILLE SAINT LAURENT A8, H4S 1Y2. The company can be reached via phone at 514-331-7440 or via email at [email protected]

This page was last updated on 12/2/2020 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.